AI Article Synopsis
- - Ensifentrine is a new inhaler medication that targets specific enzymes (PDE3 and PDE4) to enhance bronchodilation and lower inflammation in the lungs, while causing few side effects throughout the rest of the body.
- - Research, including both preclinical and clinical trials, has shown that Ensifentrine can improve lung function and reduce the frequency of severe asthma or COPD episodes.
- - The US Food and Drug Administration is currently reviewing Ensifentrine, with a decision on its approval anticipated in 2024.
Article Abstract
Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771716 | PMC |
| http://dx.doi.org/10.2147/COPD.S385811 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date.
Int J Chron Obstruct Pulmon Dis
January 2024
University of Kentucky College of Medicine, Lexington, KY, USA.
Article Synopsis
- - Ensifentrine is a new inhaler medication that targets specific enzymes (PDE3 and PDE4) to enhance bronchodilation and lower inflammation in the lungs, while causing few side effects throughout the rest of the body.
- - Research, including both preclinical and clinical trials, has shown that Ensifentrine can improve lung function and reduce the frequency of severe asthma or COPD episodes.
- - The US Food and Drug Administration is currently reviewing Ensifentrine, with a decision on its approval anticipated in 2024.
Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective.
Am J Respir Crit Care Med
January 2024
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
Expert Opin Investig Drugs
October 2019
Unit of Pharmacology, Dept. Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples , Italy.
Article Synopsis
- A compound that inhibits both PDE3 and PDE4, like Ensifentrine, may improve airway function by relaxing muscles and reducing inflammation in conditions like asthma and COPD.
- Ensifentrine is currently being studied in Phase II trials, but its role in treating COPD and asthma is still unclear due to insufficient research.
- While there's potential for Ensifentrine in cystic fibrosis treatment, more rigorous studies are needed to understand its anti-inflammatory effects and solidify its therapeutic use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!